A Phase 1/2, First-in-Human, Dose Escalation and Expansion Study of BDC-4182 as a Single Agent in Patients With Advanced Gastric and Gastroesophageal Cancer
Latest Information Update: 12 May 2025
At a glance
- Drugs BDC 4182 (Primary)
- Indications Gastric cancer; Oesophageal cancer
- Focus Adverse reactions; First in man
- Sponsors Bolt Biotherapeutics
Most Recent Events
- 04 May 2025 Status changed from not yet recruiting to recruiting.
- 15 Apr 2025 Status changed from planning to not yet recruiting.
- 24 Mar 2025 According to a Bolt Biotherapeutics media release, company is Finalizing preparations for this trial.dose escalation trial is planned to start in Australia in the second quarter of 2025.